000285565 001__ 285565
000285565 005__ 20240229155112.0
000285565 0247_ $$2doi$$a10.1186/s12916-023-03114-z
000285565 0247_ $$2pmid$$apmid:37993940
000285565 0247_ $$2altmetric$$aaltmetric:156738436
000285565 037__ $$aDKFZ-2023-02431
000285565 041__ $$aEnglish
000285565 082__ $$a610
000285565 1001_ $$aFontvieille, Emma$$b0
000285565 245__ $$aBody mass index and cancer risk among adults with and without cardiometabolic diseases: evidence from the EPIC and UK Biobank prospective cohort studies.
000285565 260__ $$aHeidelberg [u.a.]$$bSpringer$$c2023
000285565 3367_ $$2DRIVER$$aarticle
000285565 3367_ $$2DataCite$$aOutput Types/Journal article
000285565 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1700748910_19796
000285565 3367_ $$2BibTeX$$aARTICLE
000285565 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285565 3367_ $$00$$2EndNote$$aJournal Article
000285565 520__ $$aWhether cancer risk associated with a higher body mass index (BMI), a surrogate measure of adiposity, differs among adults with and without cardiovascular diseases (CVD) and/or type 2 diabetes (T2D) is unclear. The primary aim of this study was to evaluate separate and joint associations of BMI and CVD/T2D with the risk of cancer.This is an individual participant data meta-analysis of two prospective cohort studies, the UK Biobank (UKB) and the European Prospective Investigation into Cancer and nutrition (EPIC), with a total of 577,343 adults, free of cancer, T2D, and CVD at recruitment. We used Cox proportional hazard regressions to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between BMI and incidence of obesity-related cancer and in turn overall cancer with a multiplicative interaction between BMI and the two cardiometabolic diseases (CMD). HRs and 95% CIs for separate and joint associations for categories of overweight/obesity and CMD status were estimated, and additive interaction was quantified through relative excess risk due to interaction (RERI).In the meta-analysis of both cohorts, BMI (per ~ 5 kg/m2) was positively associated with the risk of obesity-related cancer among participants without a CMD (HR: 1.11, 95%CI: 1.07,1.16), among participants with T2D (HR: 1.11, 95% CI: 1.05,1.18), among participants with CVD (HR: 1.17, 95% CI: 1.11,1.24), and suggestively positive among those with both T2D and CVD (HR: 1.09, 95% CI: 0.94,1.25). An additive interaction between obesity (BMI ≥ 30 kg/m2) and CVD with the risk of overall cancer translated into a meta-analytical RERI of 0.28 (95% CI: 0.09-0.47).Irrespective of CMD status, higher BMI increased the risk of obesity-related cancer among European adults. The additive interaction between obesity and CVD suggests that obesity prevention would translate into a greater cancer risk reduction among population groups with CVD than among the general population.
000285565 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000285565 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285565 650_7 $$2Other$$aCardiovascular diseases
000285565 650_7 $$2Other$$aComorbidities
000285565 650_7 $$2Other$$aMultimorbidity
000285565 650_7 $$2Other$$aObesity
000285565 650_7 $$2Other$$aObesity-related cancers
000285565 650_7 $$2Other$$aType 2 diabetes
000285565 7001_ $$aViallon, Vivian$$b1
000285565 7001_ $$0P:(DE-HGF)0$$aRecalde, Martina$$b2
000285565 7001_ $$aCordova, Reynalda$$b3
000285565 7001_ $$aJansana, Anna$$b4
000285565 7001_ $$aPeruchet-Noray, Laia$$b5
000285565 7001_ $$aLennon, Hannah$$b6
000285565 7001_ $$aHeath, Alicia K$$b7
000285565 7001_ $$aAune, Dagfinn$$b8
000285565 7001_ $$aChristakoudi, Sofia$$b9
000285565 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b10$$udkfz
000285565 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b11$$udkfz
000285565 7001_ $$aInan-Eroglu, Elif$$b12
000285565 7001_ $$aSchulze, Matthias B$$b13
000285565 7001_ $$aMellemkjær, Lene$$b14
000285565 7001_ $$aTjønneland, Anne$$b15
000285565 7001_ $$aOvervad, Kim$$b16
000285565 7001_ $$aFarràs, Marta$$b17
000285565 7001_ $$aPetrova, Dafina$$b18
000285565 7001_ $$aAmiano, Pilar$$b19
000285565 7001_ $$aChirlaque, María-Dolores$$b20
000285565 7001_ $$aMoreno-Iribas, Conchi$$b21
000285565 7001_ $$aTin Tin, Sandar$$b22
000285565 7001_ $$aMasala, Giovanna$$b23
000285565 7001_ $$aSieri, Sabina$$b24
000285565 7001_ $$aRicceri, Fulvio$$b25
000285565 7001_ $$aPanico, Salvatore$$b26
000285565 7001_ $$aMay, Anne M$$b27
000285565 7001_ $$aMonninkhof, Evelyn M$$b28
000285565 7001_ $$aWeiderpass, Elisabete$$b29
000285565 7001_ $$aGunter, Marc J$$b30
000285565 7001_ $$aFerrari, Pietro$$b31
000285565 7001_ $$00000-0001-8648-4998$$aFreisling, Heinz$$b32
000285565 773__ $$0PERI:(DE-600)2131669-7$$a10.1186/s12916-023-03114-z$$gVol. 21, no. 1, p. 418$$n1$$p418$$tBMC medicine$$v21$$x1741-7015$$y2023
000285565 909CO $$ooai:inrepo02.dkfz.de:285565$$pVDB
000285565 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000285565 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000285565 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000285565 9141_ $$y2023
000285565 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC MED : 2022$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:07:15Z
000285565 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:07:15Z
000285565 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2023-05-02T09:07:15Z
000285565 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBMC MED : 2022$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-25
000285565 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-25
000285565 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000285565 980__ $$ajournal
000285565 980__ $$aVDB
000285565 980__ $$aI:(DE-He78)C020-20160331
000285565 980__ $$aUNRESTRICTED